209 related articles for article (PubMed ID: 36049495)
1. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A; Spata E; Emberson J; Davies K; Halls H; Holland L; Wilson K; Reith C; Child AH; Clayton T; Dodd M; Flather M; Jin XY; Sandor G; Groenink M; Mulder B; De Backer J; Evangelista A; Forteza A; Teixido-Turà G; Boileau C; Jondeau G; Milleron O; Lacro RV; Sleeper LA; Chiu HH; Wu MH; Neubauer S; Watkins H; Dietz H; Baigent C;
Lancet; 2022 Sep; 400(10355):822-831. PubMed ID: 36049495
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
[TBL] [Abstract][Full Text] [Related]
3. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
Kang YN; Chi SC; Wu MH; Chiu HH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor Blockers vs. Beta-Blocker Therapy for Marfan Syndrome: A Systematic Review and Meta-Analysis.
Wang Z; Deng X; Kang X; Hu A
Ann Vasc Surg; 2022 May; 82():347-361. PubMed ID: 34998935
[TBL] [Abstract][Full Text] [Related]
5. Beta-blockers for preventing aortic dissection in Marfan syndrome.
Koo HK; Lawrence KA; Musini VM
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011103. PubMed ID: 29110304
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
Thakur V; Rankin KN; Hartling L; Mackie AS
Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
[TBL] [Abstract][Full Text] [Related]
9. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.
Pitcher A; Emberson J; Lacro RV; Sleeper LA; Stylianou M; Mahony L; Pearson GD; Groenink M; Mulder BJ; Zwinderman AH; De Backer J; De Paepe AM; Arbustini E; Erdem G; Jin XY; Flather MD; Mullen MJ; Child AH; Forteza A; Evangelista A; Chiu HH; Wu MH; Sandor G; Bhatt AB; Creager MA; Devereux RB; Loeys B; Forfar JC; Neubauer S; Watkins H; Boileau C; Jondeau G; Dietz HC; Baigent C
Am Heart J; 2015 May; 169(5):605-12. PubMed ID: 25965707
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
[TBL] [Abstract][Full Text] [Related]
12. Drug-based cardiovascular prevention in patients with Marfan Syndrome: a systematic review.
Pavasini R; Sanguettoli F; Deserio MA; Bianchi N; Zanarelli L; Fabbri G; Tonet E; Passarini G; Serenelli M; Campo G
Minerva Cardiol Angiol; 2023 Dec; 71(6):611-621. PubMed ID: 36939732
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
Robertson DM; Truong DT; Cox DA; Carmichael HL; Ou Z; Minich LL; Williams RV; Selamet Tierney ES
Pediatr Cardiol; 2023 Mar; 44(3):618-623. PubMed ID: 35902413
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
16. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Mullen M; Jin XY; Child A; Stuart AG; Dodd M; Aragon-Martin JA; Gaze D; Kiotsekoglou A; Yuan L; Hu J; Foley C; Van Dyck L; Knight R; Clayton T; Swan L; Thomson JDR; Erdem G; Crossman D; Flather M;
Lancet; 2019 Dec; 394(10216):2263-2270. PubMed ID: 31836196
[TBL] [Abstract][Full Text] [Related]
17. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial.
Ahimastos AA; Aggarwal A; D'Orsa KM; Formosa MF; White AJ; Savarirayan R; Dart AM; Kingwell BA
JAMA; 2007 Oct; 298(13):1539-47. PubMed ID: 17911499
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
Zhang L; Zeng X; Fu P; Wu HM
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
20. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
Singh MN; Lacro RV
Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
